EQ — Equillium, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1746466 ·
Last close
$1.21
Market Cap
$99.61M
52W High
$3.54
52W Low
$0.81
ADV30
453,256
Next earnings
2026-11-12
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,048,000 -4,583,000 55,811,000 53,322,000 3,132,000
Jun 2026 0 — -5,155,000 -4,693,000 58,666,000 57,164,000 2,650,000
Mar 2026 0 — -5,610,000 -5,311,000 63,083,000 61,322,000 3,596,000
Dec 2025 0 — -3,962,000 -3,775,000 31,887,000 30,277,000 3,290,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-19,972,000
Investing CF
$-106,000
Financing CF
$65,740,000
CapEx
$-122,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.20
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-226,209,000
Inventory
—
Receivables
$108,000
ST Investments
$0
EBIT TTM
$-19,302,000
Pretax Income TTM
$-18,009,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -23,634,000 -22,398,000 31,887,000 3,290,000 28,597,000 -22,746,000
Dec 2024 41,095,000 -8,269,000 -8,067,000 25,604,000 6,543,000 19,061,000 -19,026,000
Dec 2023 36,084,000 -14,522,000 -13,335,000 50,530,000 27,957,000 22,573,000 -21,783,000
Dec 2022 15,759,000 -39,027,000 -62,428,000 78,421,000 46,479,000 31,942,000 -8,733,000

TTM Snapshot

Revenues TTM
$1,356,000
NetIncome TTM
$-18,009,000
OpCashFlow TTM
—
Assets (Latest)
$58,666,000
Forward EPS
$-0.23

Peers — same industry

TickerNameMarket CapLastDaily %
ADAG Adagene Inc. $99.37M $1.48 —
IMUX IMMUNIC, INC. $100.01M $7.33 —
HSTC HST Global, Inc. $99.00M $0.70 —
UNCY Unicycive Therapeutics, Inc. $101.35M $3.70 —
OGI ORGANIGRAM GLOBAL INC. $101.90M $0.71 —

News headlines (Yahoo Finance, 1h cache)

Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
2026-11-12 21:05 · Yahoo
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
2026-10-26 12:30 · Yahoo
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
2026-10-06 20:05 · Yahoo
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
2026-10-05 20:05 · Yahoo
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
2026-09-27 22:01 · Yahoo
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
2026-09-16 12:30 · Yahoo
Equillium to Participate in Upcoming Investor Conferences
2026-09-02 12:30 · Yahoo
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-13 20:05 · Yahoo
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
2026-05-20 20:05 · Yahoo
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-13 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.